HealthSupreme Court Questions High Medicine Markups, Suggests 16% MRP Cap
The Supreme Court has criticized the steep markups on cancer drugs and questioned why medicine MRPs are not capped at 16% above retailer prices. The court described the pricing disparity as 'carnage' and noted that private hospitals operate more like industries than service providers, highlighting concerns over exorbitant drug prices.
Live Law·11h ago



